Clinical trial
Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia
NCT00004052 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00004052 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia |
| Official title | Phase II, Multicenter Vaccination of Patients With Chronic Myelogenous Leukemia With a Multivalent Tumor Specific Breakpoint Peptide Vaccine |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological |
| Interventions | QS21, bcr-abl peptide vaccine |
| Enrollment | 24 |
| Start date | Mar 1, 1999 |
| Primary completion | Aug 1, 2005 |
| Completion | Aug 1, 2005 |
| First posted | May 8, 2003 |
| Last update posted | Jun 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: